Di Bisceglie AM, et al. Iron Reduction as an 
                        Adjuvant to Interferon Therapy in Patients With Chronic 
                        Hepatitis C Who Have Previously Not Responded to Interferon: 
                        A Multicenter, Prospective, Randomized, 
                        Controlled Trial.  Hepatology 2000 Jul;32(1):135-138 
                        
                      
Hepatic iron concentration has consistently been observed 
                        as being directly correlated with the response to interferon 
                        therapy in chronic hepatitis C virus (HCV).  We 
                        therefore conducted a randomized, controlled trial comparing 
                        iron reduction by phlebotomy with iron reduction followed 
                        by retreatment with interferon in 96 patients with chronic 
                        hepatitis C who had previously not responded to a course 
                        of interferon.  During the initial phase when all 
                        patients were undergoing phlebotomy, we found that serum 
                        alanine transaminase (ALT) activities decreased 
                        but by less than 50% from baseline in 67 patients (89%), 
                        decreased by more than 50% in 12 patients (13%) 
                        and became normal in 9 patients (9%) with no 
                        overall change in HCV-RNA levels.
                      Subsequently no patient in either treatment group achieved 
                        a sustained virologic response.  Improvements in 
                        necroinflammatory changes were noted in liver biopsy specimens 
                        in those patients receiving phlebotomy plus interferon 
                        (mean index 8.59 vs. 7.37, P <.05).  A 
                        slight but not statistically significant decrease in histologic 
                        activity index was noted in those subjects treated by 
                        phlebotomy alone (mean index 8.4 vs. 7.75, P not significant). 
                        We conclude that, although prior phlebotomy therapy does 
                        not improve the rate of sustained response to interferon 
                        retreatment, it does result in less liver injury manifested 
                        by a decrease in serum transaminase activity and a slight 
                        improvement in liver histopathology.
                      Comment: Phlebotomy 
                        generally involves drawing one pint of blood at a time 
                        to reduce red blood cells and blood iron.This study showed 
                        that this procedure decreased damage to liver cells.
                      
                      I have been telling people and doctors this for years! 
                        It makes a big difference in 25% of men and post menopausal 
                        women. It makes a difference even if there is not a obvious 
                        iron over load.
                      Doctors will not perform this procedure. The reason is 
                        because most physician's malpractice insurance does not 
                        cover Phlebotomy. Chelation doctors malpractice insurance 
                        does and so they are the people to see for this much needed 
                        therapy.
                      In good health
                      Lloyd